Trevena, Inc. (TRVN)
USD 1.27
(-0.78%)
USD 1.27
(-0.78%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.45 Million USD | 142.35% |
| 2022 | -3.43 Million USD | -787.86% |
| 2021 | -387 Thousand USD | -113.4% |
| 2020 | 2.88 Million USD | 3849.35% |
| 2019 | -77 Thousand USD | -101.34% |
| 2018 | 5.73 Million USD | 1269.8% |
| 2017 | -490 Thousand USD | -113.07% |
| 2016 | 3.75 Million USD | 109.91% |
| 2015 | -37.82 Million USD | 6.72% |
| 2014 | -40.54 Million USD | -117.68% |
| 2013 | -18.62 Million USD | -49.17% |
| 2012 | -12.48 Million USD | -615.71% |
| 2011 | 2.42 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 133 Thousand USD | 185.26% |
| 2024 Q1 | -156 Thousand USD | 90.22% |
| 2023 Q2 | 2.93 Million USD | 2523.97% |
| 2023 FY | 562 Thousand USD | 116.36% |
| 2023 Q4 | -1.59 Million USD | -32000.0% |
| 2023 Q3 | 5000.00 USD | -99.83% |
| 2023 Q1 | -121 Thousand USD | 46.93% |
| 2022 Q1 | -187 Thousand USD | 44.18% |
| 2022 FY | -3.43 Million USD | -787.86% |
| 2022 Q4 | -228 Thousand USD | 91.87% |
| 2022 Q3 | -2.8 Million USD | -1199.07% |
| 2022 Q2 | -216 Thousand USD | -15.51% |
| 2021 FY | -387 Thousand USD | -113.4% |
| 2021 Q2 | -80 Thousand USD | -273.91% |
| 2021 Q4 | -335 Thousand USD | -1761.11% |
| 2021 Q1 | 46 Thousand USD | 140.71% |
| 2021 Q3 | -18 Thousand USD | 77.5% |
| 2020 Q4 | -113 Thousand USD | -103.77% |
| 2020 Q1 | - USD | -100.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | 2.88 Million USD | 3849.35% |
| 2020 Q3 | 3 Million USD | 0.0% |
| 2019 Q4 | 31 Thousand USD | 0.0% |
| 2019 Q3 | - USD | 100.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 Q2 | -108 Thousand USD | 0.0% |
| 2019 FY | -77 Thousand USD | -101.34% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 5.73 Million USD | 1269.8% |
| 2018 Q4 | 232 Thousand USD | -92.27% |
| 2018 Q3 | 3 Million USD | 20.0% |
| 2018 Q2 | 2.5 Million USD | 0.0% |
| 2017 Q2 | -15.49 Million USD | 3.71% |
| 2017 Q1 | -16.09 Million USD | 48.82% |
| 2017 FY | -490 Thousand USD | -113.07% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 100.0% |
| 2016 Q1 | -13.87 Million USD | -18.88% |
| 2016 Q2 | -15.32 Million USD | -10.45% |
| 2016 FY | 3.75 Million USD | 109.91% |
| 2016 Q4 | -31.45 Million USD | -32.85% |
| 2016 Q3 | -23.67 Million USD | -54.45% |
| 2015 Q3 | -7.77 Million USD | 7.44% |
| 2015 Q1 | -9.97 Million USD | 8.29% |
| 2015 Q2 | -8.4 Million USD | 15.78% |
| 2015 FY | -37.82 Million USD | 6.72% |
| 2015 Q4 | -11.67 Million USD | -50.15% |
| 2014 Q2 | -9.03 Million USD | -18.31% |
| 2014 Q1 | -7.63 Million USD | -14.66% |
| 2014 FY | -40.54 Million USD | -117.68% |
| 2014 Q4 | -10.87 Million USD | 16.38% |
| 2014 Q3 | -13 Million USD | -44.02% |
| 2013 Q2 | -3.4 Million USD | -63.99% |
| 2013 Q1 | -2.07 Million USD | 16.88% |
| 2013 Q4 | -6.65 Million USD | -0.42% |
| 2013 FY | -18.62 Million USD | -49.17% |
| 2013 Q3 | -6.62 Million USD | -94.95% |
| 2012 Q4 | -2.49 Million USD | 23.23% |
| 2012 Q3 | -3.25 Million USD | 0.0% |
| 2012 FY | -12.48 Million USD | -615.71% |
| 2011 FY | 2.42 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | -763.051% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 682.0% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 364.065% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 917.416% |
| Better Therapeutics, Inc. | -2.72 Million USD | 153.316% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 205.054% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | -244.206% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 106.348% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | 242.439% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 120.516% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 661.776% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | 2861.016% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 152.04% |
| Molecular Templates, Inc. | 50.39 Million USD | 97.113% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 1319.666% |
| NexImmune, Inc. | -1.02 Million USD | 241.955% |
| Orgenesis Inc. | -5.72 Million USD | 125.415% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 105.673% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | 31723.56% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 95.049% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 397.964% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 727.155% |
| Vaxxinity, Inc. | -2.23 Million USD | 165.13% |
| Vaccinex, Inc. | -16 Million USD | 109.091% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 395.732% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | -12432.3% |